menu
    • menu

    Company profile for Ritter Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Our lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. RP-G28 has been studied in Phase 2 trials and is now in Phase 3 clinical development. We are further exploring the functionality and ...
    Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Our lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. RP-G28 has been studied in Phase 2 trials and is now in Phase 3 clinical development. We are further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno-oncology, metabolic, and liver disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ritter PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1880 Century Park East #1000 Los Angeles, CA 90067
    Telephone
    Telephone
    310-203-1000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ritterpharmaceuticals.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ritter Pharma Announces Expected Closing of Merger Transaction with Qualigen
    Ritter Pharma Announces Expected Closing of Merger Transaction with Qualigen

    22 May 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/05/22/2037739/0/en/Ritter-Pharmaceuticals-Inc-Announces-Expected-Closing-of-Merger-Transaction-with-Qualigen-Inc.html

    GLOBENEWSWIRE
    22 May 2020
    Share Share
    Ritter Pharma Announces Stockholder Approval of Proposals Merger Qualigen
    Ritter Pharma Announces Stockholder Approval of Proposals Merger Qualigen

    19 May 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/05/19/2035602/0/en/Ritter-Pharmaceuticals-Inc-Announces-Stockholder-Approval-of-Proposals-Required-for-Merger-Transaction-with-Qualigen-Inc.html

    GLOBENEWSWIRE
    19 May 2020
    Share Share
    Ritter Reports Financial Results for the First Quarter Ended March 31, 2020
    Ritter Reports Financial Results for the First Quarter Ended March 31, 2020

    01 May 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/ritter-pharmaceuticals-reports-financial-results-for-the-first-quarter-ended-march-31-2020/

    BIOSPACE
    01 May 2020
    Share Share
    Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger
    Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger

    28 Apr 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/04/28/2023214/0/en/Ritter-Pharmaceuticals-Inc-Urges-Stockholders-to-Vote-Now-on-Proposed-Merger-with-Biotech-Company-Qualigen-Inc.html

    GLOBENEWSWIRE
    28 Apr 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search